ArticleFrontiers in pharmacology2021

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.

Qiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.